AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 4.53 |
Market Cap | 50.48M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -4.35 |
PE Ratio (ttm) | -1.15 |
Forward PE | n/a |
Analyst | Buy |
Ask | 5.51 |
Volume | 46,221 |
Avg. Volume (20D) | 58,748 |
Open | 5.00 |
Previous Close | 5.02 |
Day's Range | 4.96 - 5.11 |
52-Week Range | 4.82 - 31.50 |
Beta | undefined |
About OPTN
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb c...
Analyst Forecast
According to 3 analyst ratings, the average rating for OPTN stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 258.57% from the latest price.
Next Earnings Release
Analysts project revenue of $28.21M, reflecting a 42.01% YoY growth and earnings per share of -0.45, making a -66.67% decrease YoY.